ClinicalTrials.gg
CompletedNCT00357968PRINCIPLEUpdated Aug 31, 2010Results posted

Trial in Subjects Undergoing Cardiac Catheterization With Planned Percutaneous Coronary Intervention With Stenting

A Phase 2 interventional study of Prasugrel and Clopidogrel in Coronary Artery Disease, sponsored by Eli Lilly and Company. Completed at 16 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-08-31.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
201
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies testing prasugrel in Coronary Artery Disease — 4 open to participants now, 4 under way, 1 of them phase 3. prasugrel · Coronary Artery Disease.

Enrollment
11th of 40
201 · median 84
Started
2006
with 1 other
Phase 2
4 of 40
none open now
Registered
3rd of 40
by date
Lead sponsor
7 of 40
Eli Lilly and Company

Among the 40 studies testing prasugrel in Coronary Artery Disease, this one is the 11th largest by enrollment, is one of 2 that started in 2006, is one of 4 in phase 2, and was the 3rd registered.

Coronary Artery Disease

4,863 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

4 of the 40 studies testing prasugrel in Coronary Artery Disease are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About prasugrel

prasugrel: first FDA approval 2009 (EFFIENT), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 588 Coronary Artery Disease studies recruiting now, 402 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 48 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies testing prasugrel in Coronary Artery Disease, or all of them as a file.
02

Study summary

The purpose of this study is to provide information of the relative potency of prasugrel and clopidogrel on platelet function studies, inflammation, and myocyte necrosis in subjects undergoing elective percutaneous coronary intervention (PCI).

03

Conditions studied

  • Coronary Artery Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects greater than or equal to 18 years of age undergoing cardiac catheterization with planned percutaneous coronary intervention (if coronary anatomy is suitable) for an indication of chest pain +/or anginal equivalent felt by the treating physician to be related to coronary ischemia.
  • At least one of the following (a through c):

    1. Functional study (exercise, or pharmacologic) within the past 8 weeks consistent with ischemia as manifested by at least one of the following:

      1. A reversible defect on nuclear imaging.
      2. A reversible wall-motion abnormality by echocardiography.
      3. Horizontal or down-sloping ST-depressions greater than 1 mm on (ECG) (if no imaging performed).
    2. Prior coronary revascularization [percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG)].
    3. A cardiac catheterization with at least one coronary artery lesion amenable to PCI (not yet performed) within 14 days prior to enrollment.

Exclusion criteria

Exclusion Criteria:

  • Known creatine kinase-myocardial bands (CK-MB)or cardiac troponin greater than the at time of screening
  • Planned PCI for acute myocardial infarction (MI) or planned PCI within 48 hours of fibrinolytic therapy for ST segment elevation myocardial infarction (STEMI)
  • Have cardiogenic shock at the time of screening (systolic blood pressure 90 mm Hg associated with clinical evidence of end-organ hypoperfusion, or subjects requiring vasopressors to maintain systolic blood pressure over 90 mm Hg and associated with clinical evidence of end-organ hypoperfusion).
  • ventricular arrhythmias
  • Have Class IV congestive heart failure
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
201 participants (actual)

Study arms

  • Experimental
    Prasugrel to Clopidogrel

    One time oral loading dose (LD) of 60-mg Prasugrel and placebo matched to clopidogrel (plus oral enteric coated aspirin 325 mg to 500 mg is recommended) followed by 10-mg Prasugrel and placebo matched to clopidogrel taken orally once a day for 14 days. Patients cross-over to 150 mg clopidogrel and placebo matched to prasugrel taken orally once a day for the next 14 days.

    Drug: Prasugrel · Drug: Clopidogrel · Drug: Placebo for Prasugrel · Drug: Placebo for Clopidogrel

  • Active comparator
    Clopidogrel to Prasugrel

    One time oral LD of 600 mg clopidogrel and placebo matched to prasugrel (plus oral enteric coated aspirin 325 mg to 500 mg is recommended) followed by 150 mg clopidogrel and placebo matched to prasugrel taken orally once a day for 14 days. Patients cross-over to 10 mg prasugrel and placebo tablets matched to clopidogrel taken orally once a day for the next 14 days.

    Drug: Prasugrel · Drug: Clopidogrel · Drug: Placebo for Prasugrel · Drug: Placebo for Clopidogrel

Interventions

  • Administered orally

    Also known as: LY 640315, Effient, Efient

  • Administered orally

  • DrugPlacebo for Prasugrel

    Administered orally

  • DrugPlacebo for Clopidogrel

    Administered orally

06

What researchers measure

Primary outcomes

  1. Inhibition of Platelet Aggregation (IPA) to 20 Micromolar (μM) Adenosine Diphosphate (ADP) at 6 Hours After the Loading Dose

    IPA was defined as (1 - \[maximal platelet aggregation(MPA) at 6 hours after study drug treatment\]/\[MPA before drug treatment\]) x 100.

    Time frame: 6 hours after loading dose

  2. Inhibition of Platelet Aggregation to 20 μM Adenosine Diphosphate After 14 Days of Maintenance Dose Treatment

    Measures IPA during maintenance dosing before and after cross-over for each therapy. IPA was defined as (1 - \[maximal platelet aggregation(MPA) at 14 days after study drug treatment\]/\[MPA before drug treatment\]) x 100.

    Time frame: after 14 days of maintenance dosing

Secondary outcomes

  1. Inhibition of Platelet Aggregation to 20 μM Adenosine Diphosphate at 2 Hours After the Loading Dose

    IPA was defined as (1 - \[maximal platelet aggregation (MPA) at 2 hours after study drug treatment\]/\[MPA before drug treatment\]) x 100.

    Time frame: 2 hours after loading dose

  2. Number of Participants With Non-Coronary Artery Bypass Graft (CABG) Thrombolysis in Myocardial Infarction (TIMI) Major or Minor Bleeding During the First Maintenance Dose Phase

    Non-CABG-related TIMI major bleeding was any intracranial hemorrhage OR any clinically overt bleeding associated with a fall in hemoglobin \>=5 gm/dL. Non-CABG-related TIMI minor bleeding was any clinically overt bleeding associated with a fall in hemoglobin \>=3 gm/dL but \<5 gm/dL.

    Time frame: after 14 days of treatment (before cross-over)

  3. Number of Participants With Non-Coronary Artery Bypass Graft (CABG) Thrombolysis in Myocardial Infarction (TIMI) Major or Minor Bleeding During the Crossover Maintenance Dose Phase

    Non-CABG-related TIMI major bleeding was any intracranial hemorrhage OR any clinically overt bleeding associated with a fall in hemoglobin \>=5 gm/dL. Non-CABG-related TIMI minor bleeding was any clinically overt bleeding associated with a fall in hemoglobin \>=3 gm/dL but \<5 gm/dL.

    Time frame: 14 days after cross-over

  4. Number of Participants With Major Adverse Cardiac Events (MACE) During the First Maintenance Dose Phase

    Number of patients who met any of the following endpoints: cardiovascular death, myocardial infarction, stroke, subacute stent thrombosis, or urgent target vessel revascularization

    Time frame: after 14 days of treatment (before cross-over)

  5. Number of Participants With Major Adverse Cardiac Events During the Crossover Maintenance Dose Phase

    Number of patients who met any of the following endpoints: cardiovascular death, myocardial infarction, stroke, subacute stent thrombosis, or urgent target vessel revascularization

    Time frame: 14 days after cross-over

  6. Number of Hyporesponsive Participants at 6 Hours After the Loading Dose

    Number of patients with inhibition of platelet aggregation (IPA) with 20 uM adenosine diphosphate (ADP) \<20%

    Time frame: 6 hours after loading dose

  7. Number of Hyporesponsive Participants at the End of the First Maintenance Dose Phase

    Number of patients with inhibition of platelet aggregation (IPA) with 20 uM adenosine diphosphate (ADP) \<20%

    Time frame: From loading dose to day 15

  8. Number of Hyporesponsive Participants at the End of the Crossover Maintenance Dose Phase

    Number of patients with inhibition of platelet aggregation (IPA) with 20 uM adenosine diphosphate (ADP) \<20%

    Time frame: 14 days after cross-over

  9. Platelet Reactivity Index Percent (PRI%) Measured by Vasodilator-stimulated Phosphoprotein (VASP) at 2 Hours After the Loading Dose

    VASP phosphorylation in response to prostaglandin E1 (PGE1) with and without ADP was determined by whole-blood flow cytometry and was expressed as a platelet reactivity index (PRI). PRI was defined as \[(MFI(with PGE1) - MFI (with PGE1 and ADP))/MFI(with PGE1) x 100\] where MFI is mean fluorescence index. A lower PRI indicates greater antiplatelet effect.

    Time frame: 2 hours after loading dose

  10. Platelet Reactivity Index Percent (PRI%) Measured by Vasodilator-stimulated Phosphoprotein (VASP) at 6 Hours After the Loading Dose

    VASP phosphorylation in response to prostaglandin E1 (PGE1) with and without ADP was determined by whole-blood flow cytometry and was expressed as a platelet reactivity index (PRI). PRI was defined as \[(MFI(with PGE1) - MFI (with PGE1 and ADP))/MFI(with PGE1) x 100\] where MFI is mean fluorescence index. A lower PRI indicates greater antiplatelet effect.

    Time frame: 6 hours after loading dose

  11. Platelet Reactivity Index Percent (PRI%) Measured by Vasodilator-stimulated Phosphoprotein (VASP) 18 to 24 Hours After the Loading Dose

    VASP phosphorylation in response to prostaglandin E1 (PGE1) with and without ADP was determined by whole-blood flow cytometry and was expressed as a platelet reactivity index (PRI). PRI was defined as \[(MFI(with PGE1) - MFI (with PGE1 and ADP))/MFI(with PGE1) x 100\] where MFI is mean flourescence index. A lower PRI indicates greater antiplatelet effect.

    Time frame: 18 to 24 hours after loading dose

  12. Platelet Reactivity Index Percent (PRI%) Measured by Vasodilator-stimulated Phosphoprotein (VASP) After 14 Days of Maintenance Dose Treatment

    VASP phosphorylation in response to prostaglandin E1 (PGE1) with and without ADP was determined by whole-blood flow cytometry and was expressed as a platelet reactivity index (PRI). PRI was defined as \[(MFI(with PGE1) - MFI (with PGE1 and ADP))/MFI(with PGE1) x 100\] where MFI is mean fluorescence index. A lower PRI indicates greater antiplatelet effect.

    Time frame: after 14 days of maintenance dosing

  13. Myonecrosis Measure: Creatine Kinase-Myocardial Bands (CK-MB) at 6 Hours After the Loading Dose

    Mean CK-MB at 6 hours after loading dose. CK-MB is a biomarker for myonecrosis

    Time frame: 6 hours after loading dose

  14. Myonecrosis Measure: Creatine Kinase-Myocardial Bands (CK-MB) 18 to 24 Hours After the Loading Dose

    Mean CK-MB at 18-24 hours after loading dose. CK-MB is a biomarker for myonecrosis.

    Time frame: 18 to 24 hours after loading dose

  15. Myonecrosis Measure: Cardiac Troponin at 6 Hours After the Loading Dose

    Mean troponin level at 6 hours after the loading dose. Troponin is a biomarker for myonecrosis.

    Time frame: 6 hours after loading dose

  16. Myonecrosis Measure: Cardiac Troponin 18 to 24 Hours After the Loading Dose

    Mean troponin level at 18 to 24 hours after the loading dose. Troponin is a biomarker for myonecrosis.

    Time frame: 18 to 24 hours after loading dose

07

Results

Posted Aug 9, 2010

Participant flow

First Maintenance Dose Phase
Participant flow — First Maintenance Dose Phase
MilestonePrasugrel to ClopidogrelClopidogrel to Prasugrel
Started10299
Received loading dose10299
Percutaneous coronary intervention (pci)5557
Started maintenance dose5555
Completed5455
Not completed4844
Withdrew: Not a pci patient4742
Withdrew: Withdrawal by subject12
Crossover Maintenance Dose Phase
Participant flow — Crossover Maintenance Dose Phase
MilestonePrasugrel to ClopidogrelClopidogrel to Prasugrel
Started5455
Completed5455
Not completed00

Outcome measures

PrimaryInhibition of Platelet Aggregation (IPA) to 20 Micromolar (μM) Adenosine Diphosphate (ADP) at 6 Hours After the Loading Dose

IPA was defined as (1 - \[maximal platelet aggregation(MPA) at 6 hours after study drug treatment\]/\[MPA before drug treatment\]) x 100.

Time frame:
6 hours after loading dose
Reported as:
Mean · percent inhibition
Inhibition of Platelet Aggregation (IPA) to 20 Micromolar (μM) Adenosine Diphosphate (ADP) at 6 Hours After the Loading Dose
percent inhibitionPrasugrelClopidogrel
Inhibition of Platelet Aggregation (IPA) to 20 Micromolar (μM) Adenosine Diphosphate (ADP) at 6 Hours After the Loading Dose74.81 ± 13.0131.77 ± 21.07
Statistical analysis
  • Prasugrel vs Clopidogrel · ANCOVA · p = <0.0001 · Mean difference (net): 43.21 · 95% CI 38.04 to 48.38
PrimaryInhibition of Platelet Aggregation to 20 μM Adenosine Diphosphate After 14 Days of Maintenance Dose Treatment

Measures IPA during maintenance dosing before and after cross-over for each therapy. IPA was defined as (1 - \[maximal platelet aggregation(MPA) at 14 days after study drug treatment\]/\[MPA before drug treatment\]) x 100.

Time frame:
after 14 days of maintenance dosing
Reported as:
Mean · percent inhibition
Inhibition of Platelet Aggregation to 20 μM Adenosine Diphosphate After 14 Days of Maintenance Dose Treatment
percent inhibitionPrasugrelClopidogrel
Inhibition of Platelet Aggregation to 20 μM Adenosine Diphosphate After 14 Days of Maintenance Dose Treatment61.34 ± 17.8446.06 ± 21.34
Statistical analysis
  • Prasugrel vs Clopidogrel · Mixed Models Analysis · p = <0.0001 · Ls mean difference: 14.93 · 95% CI 10.6 to 19.26
SecondaryInhibition of Platelet Aggregation to 20 μM Adenosine Diphosphate at 2 Hours After the Loading Dose

IPA was defined as (1 - \[maximal platelet aggregation (MPA) at 2 hours after study drug treatment\]/\[MPA before drug treatment\]) x 100.

Time frame:
2 hours after loading dose
Reported as:
Mean · percent inhibition
Inhibition of Platelet Aggregation to 20 μM Adenosine Diphosphate at 2 Hours After the Loading Dose
percent inhibitionPrasugrelClopidogrel
Inhibition of Platelet Aggregation to 20 μM Adenosine Diphosphate at 2 Hours After the Loading Dose64.54 ± 20.4320.32 ± 20.22
Statistical analysis
  • Prasugrel vs Clopidogrel · ANCOVA · p = <0.0001 · Mean difference (net): 44.75 · 95% CI 38.35 to 51.15
SecondaryNumber of Participants With Non-Coronary Artery Bypass Graft (CABG) Thrombolysis in Myocardial Infarction (TIMI) Major or Minor Bleeding During the First Maintenance Dose Phase

Non-CABG-related TIMI major bleeding was any intracranial hemorrhage OR any clinically overt bleeding associated with a fall in hemoglobin \>=5 gm/dL. Non-CABG-related TIMI minor bleeding was any clinically overt bleeding associated with a fall in hemoglobin \>=3 gm/dL but \<5 gm/dL.

Time frame:
after 14 days of treatment (before cross-over)
Reported as:
Number · participants
Number of Participants With Non-Coronary Artery Bypass Graft (CABG) Thrombolysis in Myocardial Infarction (TIMI) Major or Minor Bleeding During the First Maintenance Dose Phase
participantsPrasugrelClopidogrel
Number of Participants With Non-Coronary Artery Bypass Graft (CABG) Thrombolysis in Myocardial Infarction (TIMI) Major or Minor Bleeding During the First Maintenance Dose Phase20
SecondaryNumber of Participants With Non-Coronary Artery Bypass Graft (CABG) Thrombolysis in Myocardial Infarction (TIMI) Major or Minor Bleeding During the Crossover Maintenance Dose Phase

Non-CABG-related TIMI major bleeding was any intracranial hemorrhage OR any clinically overt bleeding associated with a fall in hemoglobin \>=5 gm/dL. Non-CABG-related TIMI minor bleeding was any clinically overt bleeding associated with a fall in hemoglobin \>=3 gm/dL but \<5 gm/dL.

Time frame:
14 days after cross-over
Reported as:
Number · participants
Number of Participants With Non-Coronary Artery Bypass Graft (CABG) Thrombolysis in Myocardial Infarction (TIMI) Major or Minor Bleeding During the Crossover Maintenance Dose Phase
participantsClopidogrelPrasugrel
Number of Participants With Non-Coronary Artery Bypass Graft (CABG) Thrombolysis in Myocardial Infarction (TIMI) Major or Minor Bleeding During the Crossover Maintenance Dose Phase00
SecondaryNumber of Participants With Major Adverse Cardiac Events (MACE) During the First Maintenance Dose Phase

Number of patients who met any of the following endpoints: cardiovascular death, myocardial infarction, stroke, subacute stent thrombosis, or urgent target vessel revascularization

Time frame:
after 14 days of treatment (before cross-over)
Reported as:
Number · participants
Number of Participants With Major Adverse Cardiac Events (MACE) During the First Maintenance Dose Phase
participantsPrasugrelClopidogrel
Number of Participants With Major Adverse Cardiac Events (MACE) During the First Maintenance Dose Phase21
SecondaryNumber of Participants With Major Adverse Cardiac Events During the Crossover Maintenance Dose Phase

Number of patients who met any of the following endpoints: cardiovascular death, myocardial infarction, stroke, subacute stent thrombosis, or urgent target vessel revascularization

Time frame:
14 days after cross-over
Reported as:
Number · participants
Number of Participants With Major Adverse Cardiac Events During the Crossover Maintenance Dose Phase
participantsClopidogrelPrasugrel
Number of Participants With Major Adverse Cardiac Events During the Crossover Maintenance Dose Phase10
SecondaryNumber of Hyporesponsive Participants at 6 Hours After the Loading Dose

Number of patients with inhibition of platelet aggregation (IPA) with 20 uM adenosine diphosphate (ADP) \<20%

Time frame:
6 hours after loading dose
Reported as:
Number · participants
Number of Hyporesponsive Participants at 6 Hours After the Loading Dose
participantsPrasugrelClopidogrel
Number of Hyporesponsive Participants at 6 Hours After the Loading Dose021
Statistical analysis
  • Prasugrel vs Clopidogrel · Chi-squared · p = <0.0001
SecondaryNumber of Hyporesponsive Participants at the End of the First Maintenance Dose Phase

Number of patients with inhibition of platelet aggregation (IPA) with 20 uM adenosine diphosphate (ADP) \<20%

Time frame:
From loading dose to day 15
Reported as:
Number · participants
Number of Hyporesponsive Participants at the End of the First Maintenance Dose Phase
participantsPrasugrelClopidogrel
Number of Hyporesponsive Participants at the End of the First Maintenance Dose Phase17
Statistical analysis
  • Prasugrel vs Clopidogrel · Fisher Exact · p = 0.0629
SecondaryNumber of Hyporesponsive Participants at the End of the Crossover Maintenance Dose Phase

Number of patients with inhibition of platelet aggregation (IPA) with 20 uM adenosine diphosphate (ADP) \<20%

Time frame:
14 days after cross-over
Reported as:
Number · participants
Number of Hyporesponsive Participants at the End of the Crossover Maintenance Dose Phase
participantsClopidogrelPrasugrel
Number of Hyporesponsive Participants at the End of the Crossover Maintenance Dose Phase41
Statistical analysis
  • Clopidogrel vs Prasugrel · Fisher Exact · p = 0.1827
SecondaryPlatelet Reactivity Index Percent (PRI%) Measured by Vasodilator-stimulated Phosphoprotein (VASP) at 2 Hours After the Loading Dose

VASP phosphorylation in response to prostaglandin E1 (PGE1) with and without ADP was determined by whole-blood flow cytometry and was expressed as a platelet reactivity index (PRI). PRI was defined as \[(MFI(with PGE1) - MFI (with PGE1 and ADP))/MFI(with PGE1) x 100\] where MFI is mean fluorescence index. A lower PRI indicates greater antiplatelet effect.

Time frame:
2 hours after loading dose
Reported as:
Mean · percent (%) platelet reactivity index
Platelet Reactivity Index Percent (PRI%) Measured by Vasodilator-stimulated Phosphoprotein (VASP) at 2 Hours After the Loading Dose
percent (%) platelet reactivity indexPrasugrelClopidogrel
Platelet Reactivity Index Percent (PRI%) Measured by Vasodilator-stimulated Phosphoprotein (VASP) at 2 Hours After the Loading Dose21.5 ± 27.0675.0 ± 16.91
Statistical analysis
  • Prasugrel vs Clopidogrel · ANCOVA · p = <0.0001 · Mean difference (net): -54.3 · 95% CI -61.2 to -47.4
SecondaryPlatelet Reactivity Index Percent (PRI%) Measured by Vasodilator-stimulated Phosphoprotein (VASP) at 6 Hours After the Loading Dose

VASP phosphorylation in response to prostaglandin E1 (PGE1) with and without ADP was determined by whole-blood flow cytometry and was expressed as a platelet reactivity index (PRI). PRI was defined as \[(MFI(with PGE1) - MFI (with PGE1 and ADP))/MFI(with PGE1) x 100\] where MFI is mean fluorescence index. A lower PRI indicates greater antiplatelet effect.

Time frame:
6 hours after loading dose
Reported as:
Mean · percent (%) platelet reactivity index
Platelet Reactivity Index Percent (PRI%) Measured by Vasodilator-stimulated Phosphoprotein (VASP) at 6 Hours After the Loading Dose
percent (%) platelet reactivity indexPrasugrelClopidogrel
Platelet Reactivity Index Percent (PRI%) Measured by Vasodilator-stimulated Phosphoprotein (VASP) at 6 Hours After the Loading Dose7.4 ± 16.6668.4 ± 21.18
Statistical analysis
  • Prasugrel vs Clopidogrel · ANCOVA · p = <0.0001 · Mean difference (net): -60.5 · 95% CI -67.1 to -54.0
SecondaryPlatelet Reactivity Index Percent (PRI%) Measured by Vasodilator-stimulated Phosphoprotein (VASP) 18 to 24 Hours After the Loading Dose

VASP phosphorylation in response to prostaglandin E1 (PGE1) with and without ADP was determined by whole-blood flow cytometry and was expressed as a platelet reactivity index (PRI). PRI was defined as \[(MFI(with PGE1) - MFI (with PGE1 and ADP))/MFI(with PGE1) x 100\] where MFI is mean flourescence index. A lower PRI indicates greater antiplatelet effect.

Time frame:
18 to 24 hours after loading dose
Reported as:
Mean · percent (%) platelet reactivity index
Platelet Reactivity Index Percent (PRI%) Measured by Vasodilator-stimulated Phosphoprotein (VASP) 18 to 24 Hours After the Loading Dose
percent (%) platelet reactivity indexPrasugrelClopidogrel
Platelet Reactivity Index Percent (PRI%) Measured by Vasodilator-stimulated Phosphoprotein (VASP) 18 to 24 Hours After the Loading Dose10.3 ± 15.6364.3 ± 18.72
Statistical analysis
  • Prasugrel vs Clopidogrel · ANCOVA · p = <0.0001 · Mean difference (net): -56.2 · 95% CI -63.2 to -49.2
SecondaryPlatelet Reactivity Index Percent (PRI%) Measured by Vasodilator-stimulated Phosphoprotein (VASP) After 14 Days of Maintenance Dose Treatment

VASP phosphorylation in response to prostaglandin E1 (PGE1) with and without ADP was determined by whole-blood flow cytometry and was expressed as a platelet reactivity index (PRI). PRI was defined as \[(MFI(with PGE1) - MFI (with PGE1 and ADP))/MFI(with PGE1) x 100\] where MFI is mean fluorescence index. A lower PRI indicates greater antiplatelet effect.

Time frame:
after 14 days of maintenance dosing
Reported as:
Mean · percent (%) platelet reactivity index
Platelet Reactivity Index Percent (PRI%) Measured by Vasodilator-stimulated Phosphoprotein (VASP) After 14 Days of Maintenance Dose Treatment
percent (%) platelet reactivity indexPrasugrelClopidogrel
Platelet Reactivity Index Percent (PRI%) Measured by Vasodilator-stimulated Phosphoprotein (VASP) After 14 Days of Maintenance Dose Treatment23.4 ± 19.1943.8 ± 23.26
Statistical analysis
  • Prasugrel vs Clopidogrel · Mixed Models Analysis · p = <0.0001 · Ls mean difference: -20.1 · 95% CI -25.7 to -14.5
SecondaryMyonecrosis Measure: Creatine Kinase-Myocardial Bands (CK-MB) at 6 Hours After the Loading Dose

Mean CK-MB at 6 hours after loading dose. CK-MB is a biomarker for myonecrosis

Time frame:
6 hours after loading dose
Reported as:
Mean · IU/L
Myonecrosis Measure: Creatine Kinase-Myocardial Bands (CK-MB) at 6 Hours After the Loading Dose
IU/LPrasugrelClopidogrel
Myonecrosis Measure: Creatine Kinase-Myocardial Bands (CK-MB) at 6 Hours After the Loading Dose9.16 ± 8.38.13 ± 5.16
Statistical analysis
  • Prasugrel vs Clopidogrel · ANCOVA · p = 0.7058 · Mean difference (net): -0.47 · 95% CI -2.95 to 2.00
SecondaryMyonecrosis Measure: Creatine Kinase-Myocardial Bands (CK-MB) 18 to 24 Hours After the Loading Dose

Mean CK-MB at 18-24 hours after loading dose. CK-MB is a biomarker for myonecrosis.

Time frame:
18 to 24 hours after loading dose
Reported as:
Median · IU/L
Myonecrosis Measure: Creatine Kinase-Myocardial Bands (CK-MB) 18 to 24 Hours After the Loading Dose
IU/LPrasugrelClopidogrel
Myonecrosis Measure: Creatine Kinase-Myocardial Bands (CK-MB) 18 to 24 Hours After the Loading Dose11.64 ± 8.2211.16 ± 8.72
Statistical analysis
  • Prasugrel vs Clopidogrel · ANCOVA · p = 0.4029 · Mean difference (net): -1.33 · 95% CI -4.48 to 1.82
SecondaryMyonecrosis Measure: Cardiac Troponin at 6 Hours After the Loading Dose

Mean troponin level at 6 hours after the loading dose. Troponin is a biomarker for myonecrosis.

Time frame:
6 hours after loading dose
Reported as:
Mean · ng/ml
Myonecrosis Measure: Cardiac Troponin at 6 Hours After the Loading Dose
ng/mlPrasugrelClopidogrel
Myonecrosis Measure: Cardiac Troponin at 6 Hours After the Loading Dose0.06 ± 0.2040.05 ± 0.128
Statistical analysis
  • Prasugrel vs Clopidogrel · ANCOVA · p = 0.7893 · Mean difference (net): 0.01 · 95% CI -0.06 to 0.08
SecondaryMyonecrosis Measure: Cardiac Troponin 18 to 24 Hours After the Loading Dose

Mean troponin level at 18 to 24 hours after the loading dose. Troponin is a biomarker for myonecrosis.

Time frame:
18 to 24 hours after loading dose
Reported as:
Mean · ng/ml
Myonecrosis Measure: Cardiac Troponin 18 to 24 Hours After the Loading Dose
ng/mlPrasugrelClopidogrel
Myonecrosis Measure: Cardiac Troponin 18 to 24 Hours After the Loading Dose0.12 ± 0.2730.13 ± 0.277
Statistical analysis
  • Prasugrel vs Clopidogrel · ANCOVA · p = 0.4528 · Mean difference (net): -0.04 · 95% CI -0.25 to 0.07

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Prasugrel Before Cross-over—8/102 (7.8%)40/102 (39.2%)
Clopidogrel Before Cross-over—7/99 (7.1%)40/99 (40.4%)
Prasugrel After Cross-over—1/55 (1.8%)16/55 (29.1%)
Clopidogrel After Cross-over—3/53 (5.7%)12/53 (22.6%)
Most frequent serious events
Showing 10 of 22
Most frequent serious events
EventPrasugrel Before Cross-overClopidogrel Before Cross-overPrasugrel After Cross-overClopidogrel After Cross-over
Vessel puncture site haematomaGeneral disorders2/1020/990/550/53
Acute coronary syndromeCardiac disorders0/1020/990/551/53
Borrelia infectionInfections and infestations0/1020/990/551/53
Chronic obstructive pulmonmary diseaseRespiratory, thoracic and mediastinal disorders0/1020/990/551/53
TachycardiaCardiac disorders0/1020/990/551/53
Non-cardiac chest painGeneral disorders0/1021/991/550/53
Chest discomfortGeneral disorders0/1021/990/550/53
Chest painGeneral disorders0/1021/990/550/53
DyspnoeaRespiratory, thoracic and mediastinal disorders0/1021/990/550/53
ExtrasystolesCardiac disorders0/1021/990/550/53
Most frequent other events
Showing 10 of 91
Most frequent other events
EventPrasugrel Before Cross-overClopidogrel Before Cross-overPrasugrel After Cross-overClopidogrel After Cross-over
HypotensionVascular disorders5/1021/990/550/53
Back painMusculoskeletal and connective tissue disorders4/1024/992/550/53
DyspepsiaGastrointestinal disorders1/1024/990/550/53
MyalgiaMusculoskeletal and connective tissue disorders0/1024/991/550/53
Chest painGeneral disorders4/1023/992/552/53
Groin painMusculoskeletal and connective tissue disorders4/1021/990/550/53
HaematomaVascular disorders4/1021/991/550/53
DyspnoeaRespiratory, thoracic and mediastinal disorders1/1022/991/552/53
EpistaxisReproductive system and breast disorders3/1022/992/550/53
Musculoskeletal painMusculoskeletal and connective tissue disorders1/1021/992/550/53

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Prasugrel to ClopidogrelClopidogrel to PrasugrelTotal
<=18 years000
Between 18 and 65 years464793
>=65 years5652108
Age Continuous
Age Continuous(years)Prasugrel to ClopidogrelClopidogrel to PrasugrelTotal
Mean64.0 ± 10.7363.8 ± 9.3863.9 ± 10.06
Sex: Female, Male
Sex: Female, Male(Participants)Prasugrel to ClopidogrelClopidogrel to PrasugrelTotal
Female292251
Male7377150
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Prasugrel to ClopidogrelClopidogrel to PrasugrelTotal
African347
Caucasian9794191
Native American202
West Asian011
Region of Enrollment
Region of Enrollment(participants)Prasugrel to ClopidogrelClopidogrel to PrasugrelTotal
France336
Germany5553108
Israel151328
United States293059
08

Study locations

16 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Jacksonville, Florida 32209, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Worcester, Massachusetts 01655, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ann Arbor, Michigan 48109, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Rapid City, South Dakota 57701, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lille, 59037, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Marseille, 13385, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Paris, 75013, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tours, 37044, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bad Krozingen, D-79189, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Berlin, D-12203, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Giessen, 35392, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    München, D-80636, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tubingen, 72076, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Haifa, 31096, Israel
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Jerusalem, 91120, Israel
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tel Hashomer, 52621, Israel
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2006, a primary completion of Jun 2007 and a completion of Jun 2007. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2010, 3 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 26, 2006
First posted
Jul 28, 2006
Start
Aug 2006
Primary completionActual
Jun 2007
CompletionActual
Jun 2007
Results first posted
Aug 9, 2010
Last update
Aug 31, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00357968
Collaborators
Daiichi Sankyo, The TIMI Study Group
First posted
Jul 28, 2006
Start date
Aug 2006
Primary completion
Jun 2007
Completion
Jun 2007
Results posted
Aug 9, 2010
Last update
Aug 31, 2010

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Prasugrel · Clopidogrel

Start the discussion